search
Back to results

HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program

Primary Purpose

Myocardial Infarction, Acute Coronary Syndrome, ST-segment Elevation Myocardial Infarction (STEMI)

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
HeartHome
Sponsored by
University of North Carolina, Chapel Hill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Myocardial Infarction focused on measuring Cardiac Rehabilitation

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Individuals are eligible for the HeartHome study if they meet all the following inclusion criteria:

  • Diagnosed with one of the following conditions: myocardial infarction (MI)/acute coronary syndrome (ACS), ST-elevation myocardial infarction (STEMI), non-STEMI, percutaneous coronary intervention (PCI) or stable angina;
  • Decline traditional cardiac rehab or do not respond to traditional cardiac rehab enrollment methods;
  • Willing to have a nurse visit them in their home and receive follow-up phone calls and text messages for a 12-week intervention period;
  • Understand the requirements of participation in and consent to the HeartHome program;
  • Live within a 75-mile radius of the study site.

Individuals are not eligible for the HeartHome study if they meet any of the following exclusion criteria:

  • Diagnosis of heart failure
  • Diagnosis of valvular heart disease
  • Presence of cardiac disease requiring surgery or other invasive procedure
  • Impaired mental capacity resulting in an inability to understand or follow directions and study protocol
  • Impaired functional abilities that prevent them from participating in physical activity
  • Presence of any serious medical conditions that are likely to cause premature death or to impair functional capacity
  • No access to a telephone

Sites / Locations

  • UNC Health Care

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

HeartHome Intervention

Control

Arm Description

Participants will be in the HeartHome program for a total of 12 weeks.

De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation

Outcomes

Primary Outcome Measures

Number of HeartHome patient referrals into the HeartHome program
Number of patient referrals into the HeartHome program will be measured by the total number of participants eligible to enroll in traditional cardiac rehab that were referred to the HeartHome program.
Proportion of HeartHome patient referral into the HeartHome program
Proportion of patient referrals into the HeartHome program will be measured by the number of patients referred to the HeartHome program relative to the number of patients referred to traditional cardiac rehab.
Proportion of HeartHome patient enrollments in the HeartHome program
Proportion of patient enrollments in the HeartHome program will be measured by the number of patients who enroll in the HeartHome program relative to the number of eligible patients referred to the HeartHome program. Enrollment is defined by signing the study consent form.
Participation in HeartHome's participants in-person visits
Participation in HeartHome's in-person visits will be measured by the number of in-person visits that each participant attends relative to the total number of in-person visits. The total number of visits possible per person is 5, with higher numbers associated with better participation.
Participation in HeartHome's participants interactive online classes
Participation in HeartHome's online classes will be measured by the number of online classes that each participant attends relative to the total number of interactive online classes. The total number of classes possible is 7, with higher numbers associated with better participation.
Participation in HeartHome intervention calls
Participation in HeartHome's calls will be measured by the number of calls that each participant attends relative to the total number of calls. The total number of calls possible is 8, with higher rate associated with better participation.
HeartHome intervention weekly goal adherence score
Adherence to weekly goals will be measured by participant goal achievement, which includes 33 opportunities for goal achievement and progression. The range is 0-33, with higher scores associated with greater adherence to weekly goals.
Number of sessions completed.
Sessions completed by participants will be measured by the total number of calls, interactive online classes, and in-person visits attended. The total number of sessions is 20, with higher numbers associated with higher participation. Sessions completed by the control group will be measured by the total number of exercise sessions and classes attended. The total number of sessions for the control group is 46, with higher numbers associated with higher participation.

Secondary Outcome Measures

HeartHome participants' physical function at baseline and at week 12
HeartHome participants' physical function will be measured by the six-minute walk distances at baseline and at 12 weeks. Longer distances (in meters) are associated with higher physical function.
Change in HeartHome participant's physical functioning, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' physical function will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better physical function.
Change in HeartHome participant's role limitations due to physical health, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' role limitations due to physical health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to physical health.
Change in HeartHome participant's role limitations due to emotional problems, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' role limitations due to emotional problems will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to emotional problems.
Change in HeartHome participant's energy/fatigue, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' energy/fatigue will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with higher energy/lower fatigue.
HeartHome participant's emotional well-being, sub score of RAND SF-36, assessed at baseline, week 12, and week 24.
Participants' emotional well-being will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better emotional well-being.
HeartHome participant's social functioning, sub score of RAND SF-36, evaluated at baseline, week 12, and week 24.
Participants' social functioning will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better social functioning.
HeartHome participant's bodily pain, a sub score of RAND SF-36, will be evaluated at baseline, week 12 and week 24.
Participants' bodily pain will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with less pain.
HeartHome participant's general health, sub score of RAND SF-36 at baseline, week 12, and week 24.
Participants' general health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better general health.
HeartHome participant's change of participant and control physical functioning, sub score of RAND SF-36, from baseline to week 12 to end of program
Participants' physical function will be measured by a sub score of the RAND SF-36. The range is 0-100, and higher scores are associated with better physical functioning.
HeartHome participant's blood pressure at baseline and weeks 3, 5, 7 and 12.
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Participants' and control's blood pressure at baseline and 12 weeks
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Change in HeartHome participant's reported nicotine use from baseline to week 12 and baseline to week 24.
Rates of nicotine use will be measured by the change in participant-reported number of cigarettes smoked per week and patient-report of weekly frequency of non-cigarette nicotine use from baseline to week 12, and baseline to week 24.
HeartHome participant's waist circumference from baseline to week 12.
Waist circumference will be measured in centimeters at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Negative changes in waist circumference are associated with greater weight loss.
HeartHome participant's Body Mass Index at baseline and week 12.
Body Mass Index will be calculated from the participants' weights and heights at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
Change of HeartHome participants' and control Body Mass Index from baseline to week 12
Body Mass Index will be calculated by assessing participant weight and height at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome Program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
HeartHome participant's average weekly steps walked from baseline to week 12.
Average steps walked will be calculated using electronic fitness trackers at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Higher numbers are associated with higher physical activity.
HeartHome participant's self-Reported and medical record reviewed number of hospital admissions 12 and 24 weeks after beginning of heart home program.
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of instances the participant is hospitalized in 12 and 24 weeks after the beginning of the heart home program.
HeartHome participant's self-Reported and medical record reviewed number of days hospitalized 12 and 24 weeks after beginning of heart home program.
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined days the participant spends in the hospital in 12 and 24 weeks after the beginning of the heart home program.
HeartHome participant and control number of hospital readmissions at 12 weeks
Hospital readmission will be measured using patient self-reports and medical record reviews of hospital admissions (yes/no) at 12 weeks after the start of the intervention (HeartHome program).
HeartHome participant's self-reported and medical record reviewed number of ED visits without hospital admissions 12 and 24 weeks after beginning of HeartHome program
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined visits the participant makes to the Emergency Department (ED) in 12 and 24 weeks after the beginning of the heart home program.
HeartHome participant's self-reported and medical record reviewed number of specialist visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of specialist visits will be measured using self-reported and medical record reviewed number of combined cardiology visits 12 and 24 weeks after the beginning of the heart home program.
HeartHome participant's self-reported and medical record reviewed number of primary care visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of primary care visits will be measured using self-reported and medical record reviewed number of combined primary care visits 12 and 24 weeks after the beginning of the heart home program.
HeartHome participant's self-reported and medical record reviewed number of urgent care visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of urgent care visits will be measured using self-reported and medical record reviewed number of combined urgent care visits 12 and 24 weeks after the beginning of the heart home program.
HeartHome participant's Morisky 4-Item Scale scores at baseline, week 12, and week 24.
Management of participants' medications will be measured using the Morisky 4-item scale, which includes four questions to estimate the risk of medication non-adherence. The range is 0 to 4, and lower scores are associated with lower levels of medication adherence.
HeartHome participant's change in perceived stress scale from baseline to week 12 and baseline to week 24.
Participants' stress and emotional state will be measured using the perceived stress scale, which includes ten questions about individuals' feelings and thoughts during the last month. The range is 0-40, and higher scores are associated with higher levels of perceived stress.
HeartHome participant's change in dietary risk assessment from baseline to week 12 and baseline to week 24.
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
Participants' and control's dietary risk assessment scores from baseline to week 12 to dietary risk assessment scores of control group.
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
HeartHome participant's change in PHQ-9 from baseline to week 12.
Participants' emotional state will be measured by the Patient Health Questionnaire (PHQ)-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression.
Change in participants' and control's PHQ-9 from baseline to week 12.
Participants' emotional state will be measured by the PHQ-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression, with higher scores associated with more severe levels of depression.
HeartHome participant's change in New General Self-Efficacy score from baseline to week 12 and baseline to week 24.
Participants' confidence regarding task and situational performance is measured by the New General Self-Efficacy Scale, which includes 8 questions about participant confidence. The range is 8 to 40, and higher scores are associated with higher self-efficacy.
HeartHome participant's change in knowledge of cardiac rehabilitation from baseline to 12 weeks and baseline to 24 weeks.
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.
Participants' and control's change in knowledge of cardiac rehabilitation from baseline to 12 weeks.
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.

Full Information

First Posted
October 16, 2019
Last Updated
March 23, 2022
Sponsor
University of North Carolina, Chapel Hill
search

1. Study Identification

Unique Protocol Identification Number
NCT04131816
Brief Title
HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program
Official Title
HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 10, 2019 (Actual)
Primary Completion Date
February 11, 2022 (Actual)
Study Completion Date
February 11, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of North Carolina, Chapel Hill

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this implementation trial is to execute a nurse-led, home-based cardiac rehabilitation (HBCR) program, evaluate the program's impact on patient outcomes over 6 months; and compare outcomes of HeartHome (HH) participants to a group of participants in traditional cardiac rehabilitation (CR).
Detailed Description
Despite being recognized as a class 1 recommendation by the American Heart Association (AHA), traditional CR is underused: only 20% of patients who need CR are referred, and only half of those referred enroll in the program. The primary barriers to enrollment in CR include the failure of providers to refer patients; systems that lack a clear, streamlined referral process; and patients who face multiple barriers, including knowledge, transportation, cost, time, and social-family support. The HeartHome program is adapted from MULTIFIT, an evidence-based, interdisciplinary model of care developed at Stanford University was originally designed to provide coronary risk factor modification in post-MI patients, and later modified to implement consensus guidelines for providing HBCR to individuals with CVD using nurse managed care via telephone follow-up. HeartHome will combine nurse home visits with telephone and electronic supports for participants in a HBCR program that allows them to engage in cardiac rehabilitation programs at home. In this trial, nurses will deliver the 12-week educational program to 150 participants. Participants will then complete follow-up assessments at the end of the program (3 months post enrollment), and then at 6-months post enrollment. The data collected will be compared to a control group that contains de-identified data from 150 patients that attend the traditional cardiac rehab program.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction, Acute Coronary Syndrome, ST-segment Elevation Myocardial Infarction (STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Angina, Stable
Keywords
Cardiac Rehabilitation

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HeartHome Intervention
Arm Type
Experimental
Arm Description
Participants will be in the HeartHome program for a total of 12 weeks.
Arm Title
Control
Arm Type
No Intervention
Arm Description
De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation
Intervention Type
Behavioral
Intervention Name(s)
HeartHome
Intervention Description
The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
Primary Outcome Measure Information:
Title
Number of HeartHome patient referrals into the HeartHome program
Description
Number of patient referrals into the HeartHome program will be measured by the total number of participants eligible to enroll in traditional cardiac rehab that were referred to the HeartHome program.
Time Frame
10 months after beginning of study
Title
Proportion of HeartHome patient referral into the HeartHome program
Description
Proportion of patient referrals into the HeartHome program will be measured by the number of patients referred to the HeartHome program relative to the number of patients referred to traditional cardiac rehab.
Time Frame
10 months after beginning of study
Title
Proportion of HeartHome patient enrollments in the HeartHome program
Description
Proportion of patient enrollments in the HeartHome program will be measured by the number of patients who enroll in the HeartHome program relative to the number of eligible patients referred to the HeartHome program. Enrollment is defined by signing the study consent form.
Time Frame
10 months after beginning of study
Title
Participation in HeartHome's participants in-person visits
Description
Participation in HeartHome's in-person visits will be measured by the number of in-person visits that each participant attends relative to the total number of in-person visits. The total number of visits possible per person is 5, with higher numbers associated with better participation.
Time Frame
12 weeks post HeartHome intervention start
Title
Participation in HeartHome's participants interactive online classes
Description
Participation in HeartHome's online classes will be measured by the number of online classes that each participant attends relative to the total number of interactive online classes. The total number of classes possible is 7, with higher numbers associated with better participation.
Time Frame
12 weeks post HeartHome intervention start
Title
Participation in HeartHome intervention calls
Description
Participation in HeartHome's calls will be measured by the number of calls that each participant attends relative to the total number of calls. The total number of calls possible is 8, with higher rate associated with better participation.
Time Frame
12 weeks post HeartHome intervention start
Title
HeartHome intervention weekly goal adherence score
Description
Adherence to weekly goals will be measured by participant goal achievement, which includes 33 opportunities for goal achievement and progression. The range is 0-33, with higher scores associated with greater adherence to weekly goals.
Time Frame
12 weeks post HeartHome intervention start
Title
Number of sessions completed.
Description
Sessions completed by participants will be measured by the total number of calls, interactive online classes, and in-person visits attended. The total number of sessions is 20, with higher numbers associated with higher participation. Sessions completed by the control group will be measured by the total number of exercise sessions and classes attended. The total number of sessions for the control group is 46, with higher numbers associated with higher participation.
Time Frame
13-weeks post start of HeartHome and control intervention
Secondary Outcome Measure Information:
Title
HeartHome participants' physical function at baseline and at week 12
Description
HeartHome participants' physical function will be measured by the six-minute walk distances at baseline and at 12 weeks. Longer distances (in meters) are associated with higher physical function.
Time Frame
12 weeks post start of HeartHome intervention
Title
Change in HeartHome participant's physical functioning, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Description
Change in participants' physical function will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better physical function.
Time Frame
12- and 24-weeks post start of intervention
Title
Change in HeartHome participant's role limitations due to physical health, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Description
Change in participants' role limitations due to physical health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to physical health.
Time Frame
12- and 24- weeks post start of intervention
Title
Change in HeartHome participant's role limitations due to emotional problems, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Description
Change in participants' role limitations due to emotional problems will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to emotional problems.
Time Frame
12- and 24- weeks post start of intervention
Title
Change in HeartHome participant's energy/fatigue, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Description
Change in participants' energy/fatigue will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with higher energy/lower fatigue.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant's emotional well-being, sub score of RAND SF-36, assessed at baseline, week 12, and week 24.
Description
Participants' emotional well-being will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better emotional well-being.
Time Frame
12- and 24-weeks post start of intervention
Title
HeartHome participant's social functioning, sub score of RAND SF-36, evaluated at baseline, week 12, and week 24.
Description
Participants' social functioning will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better social functioning.
Time Frame
12- and 24-weeks post start of intervention
Title
HeartHome participant's bodily pain, a sub score of RAND SF-36, will be evaluated at baseline, week 12 and week 24.
Description
Participants' bodily pain will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with less pain.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant's general health, sub score of RAND SF-36 at baseline, week 12, and week 24.
Description
Participants' general health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better general health.
Time Frame
12- and 24-weeks post start of intervention
Title
HeartHome participant's change of participant and control physical functioning, sub score of RAND SF-36, from baseline to week 12 to end of program
Description
Participants' physical function will be measured by a sub score of the RAND SF-36. The range is 0-100, and higher scores are associated with better physical functioning.
Time Frame
13-weeks post start of HeartHome and control intervention
Title
HeartHome participant's blood pressure at baseline and weeks 3, 5, 7 and 12.
Description
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Time Frame
Baseline, weeks 3, 5, 7, and 12 of intervention
Title
Participants' and control's blood pressure at baseline and 12 weeks
Description
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Time Frame
Baseline and 13-weeks post start of HeartHome and control intervention
Title
Change in HeartHome participant's reported nicotine use from baseline to week 12 and baseline to week 24.
Description
Rates of nicotine use will be measured by the change in participant-reported number of cigarettes smoked per week and patient-report of weekly frequency of non-cigarette nicotine use from baseline to week 12, and baseline to week 24.
Time Frame
12- and 24-weeks post start of intervention
Title
HeartHome participant's waist circumference from baseline to week 12.
Description
Waist circumference will be measured in centimeters at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Negative changes in waist circumference are associated with greater weight loss.
Time Frame
12 weeks post start of intervention
Title
HeartHome participant's Body Mass Index at baseline and week 12.
Description
Body Mass Index will be calculated from the participants' weights and heights at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
Time Frame
Baseline and 12 weeks post start of intervention
Title
Change of HeartHome participants' and control Body Mass Index from baseline to week 12
Description
Body Mass Index will be calculated by assessing participant weight and height at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome Program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
Time Frame
Baseline and 13-weeks post start of HeartHome and control intervention
Title
HeartHome participant's average weekly steps walked from baseline to week 12.
Description
Average steps walked will be calculated using electronic fitness trackers at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Higher numbers are associated with higher physical activity.
Time Frame
12 weeks post start of intervention
Title
HeartHome participant's self-Reported and medical record reviewed number of hospital admissions 12 and 24 weeks after beginning of heart home program.
Description
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of instances the participant is hospitalized in 12 and 24 weeks after the beginning of the heart home program.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant's self-Reported and medical record reviewed number of days hospitalized 12 and 24 weeks after beginning of heart home program.
Description
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined days the participant spends in the hospital in 12 and 24 weeks after the beginning of the heart home program.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant and control number of hospital readmissions at 12 weeks
Description
Hospital readmission will be measured using patient self-reports and medical record reviews of hospital admissions (yes/no) at 12 weeks after the start of the intervention (HeartHome program).
Time Frame
13-weeks post start of HeartHome and control intervention
Title
HeartHome participant's self-reported and medical record reviewed number of ED visits without hospital admissions 12 and 24 weeks after beginning of HeartHome program
Description
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined visits the participant makes to the Emergency Department (ED) in 12 and 24 weeks after the beginning of the heart home program.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant's self-reported and medical record reviewed number of specialist visits 12 and 24 weeks after beginning of the HeartHome program
Description
Participants' number of specialist visits will be measured using self-reported and medical record reviewed number of combined cardiology visits 12 and 24 weeks after the beginning of the heart home program.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant's self-reported and medical record reviewed number of primary care visits 12 and 24 weeks after beginning of the HeartHome program
Description
Participants' number of primary care visits will be measured using self-reported and medical record reviewed number of combined primary care visits 12 and 24 weeks after the beginning of the heart home program.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant's self-reported and medical record reviewed number of urgent care visits 12 and 24 weeks after beginning of the HeartHome program
Description
Participants' number of urgent care visits will be measured using self-reported and medical record reviewed number of combined urgent care visits 12 and 24 weeks after the beginning of the heart home program.
Time Frame
12- and 24- weeks post start of intervention
Title
HeartHome participant's Morisky 4-Item Scale scores at baseline, week 12, and week 24.
Description
Management of participants' medications will be measured using the Morisky 4-item scale, which includes four questions to estimate the risk of medication non-adherence. The range is 0 to 4, and lower scores are associated with lower levels of medication adherence.
Time Frame
12- and 24-weeks post start of intervention
Title
HeartHome participant's change in perceived stress scale from baseline to week 12 and baseline to week 24.
Description
Participants' stress and emotional state will be measured using the perceived stress scale, which includes ten questions about individuals' feelings and thoughts during the last month. The range is 0-40, and higher scores are associated with higher levels of perceived stress.
Time Frame
12 and 24 weeks post start of intervention
Title
HeartHome participant's change in dietary risk assessment from baseline to week 12 and baseline to week 24.
Description
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
Time Frame
12- and 24- weeks post start of intervention
Title
Participants' and control's dietary risk assessment scores from baseline to week 12 to dietary risk assessment scores of control group.
Description
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
Time Frame
13-weeks post start of HeartHome and control intervention
Title
HeartHome participant's change in PHQ-9 from baseline to week 12.
Description
Participants' emotional state will be measured by the Patient Health Questionnaire (PHQ)-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression.
Time Frame
12 weeks post start of intervention
Title
Change in participants' and control's PHQ-9 from baseline to week 12.
Description
Participants' emotional state will be measured by the PHQ-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression, with higher scores associated with more severe levels of depression.
Time Frame
13-weeks post start of HeartHome and control intervention
Title
HeartHome participant's change in New General Self-Efficacy score from baseline to week 12 and baseline to week 24.
Description
Participants' confidence regarding task and situational performance is measured by the New General Self-Efficacy Scale, which includes 8 questions about participant confidence. The range is 8 to 40, and higher scores are associated with higher self-efficacy.
Time Frame
12- and 24-weeks post start of intervention
Title
HeartHome participant's change in knowledge of cardiac rehabilitation from baseline to 12 weeks and baseline to 24 weeks.
Description
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.
Time Frame
12- and 24-weeks post start of intervention
Title
Participants' and control's change in knowledge of cardiac rehabilitation from baseline to 12 weeks.
Description
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.
Time Frame
13-weeks post start of HeartHome and control intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Individuals are eligible for the HeartHome study if they meet all the following inclusion criteria: Diagnosed with one of the following conditions: myocardial infarction (MI)/acute coronary syndrome (ACS), ST-elevation myocardial infarction (STEMI), non-STEMI, percutaneous coronary intervention (PCI) or stable angina; Decline traditional cardiac rehab or do not respond to traditional cardiac rehab enrollment methods; Willing to have a nurse visit them in their home and receive follow-up phone calls and text messages for a 12-week intervention period; Understand the requirements of participation in and consent to the HeartHome program; Live within a 75-mile radius of the study site. Individuals are not eligible for the HeartHome study if they meet any of the following exclusion criteria: Diagnosis of heart failure Diagnosis of valvular heart disease Presence of cardiac disease requiring surgery or other invasive procedure Impaired mental capacity resulting in an inability to understand or follow directions and study protocol Impaired functional abilities that prevent them from participating in physical activity Presence of any serious medical conditions that are likely to cause premature death or to impair functional capacity No access to a telephone
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cheryl Jones, PhD, RN
Organizational Affiliation
University of North Carolina, Chapel Hill
Official's Role
Principal Investigator
Facility Information:
Facility Name
UNC Health Care
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27514
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program

We'll reach out to this number within 24 hrs